Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer, Castration Resistant”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01934790
What this trial is testing

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Who this might be right for
Prostatic Neoplasms
Bayer 45
Early research (Phase 1)Looking for participantsNCT07824349
What this trial is testing

JUR-003 in Adult Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate CancerOligometastatic Prostate Cancer (OMPC)Metastatic Hormone Sensitive Prostate Cancer
Juri Biosciences, Inc. 210
Early research (Phase 1)Active Not RecruitingNCT04388852
What this trial is testing

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Clear Cell Renal Cell Carcinoma+7 more
M.D. Anderson Cancer Center 65
Testing effectiveness (Phase 2)Study completedNCT01619813
What this trial is testing

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 85
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Testing effectiveness (Phase 2)UnknownNCT03305224
What this trial is testing

The Combination Therapy With Ra-223 and Enzalutamide

Who this might be right for
Castration-resistant Prostate CancerBone Metastases
Taro Iguchi, MD, PHD 10
Early research (Phase 1)Study completedNCT01565746
What this trial is testing

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Who this might be right for
Prostatic Neoplasms
Bayer 19
Testing effectiveness (Phase 2)Study completedNCT04862091
What this trial is testing

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd. 69
Testing effectiveness (Phase 2)Ended earlyNCT01735396
What this trial is testing

Abiraterone Acetate Trial in African American Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Icahn School of Medicine at Mount Sinai 11
Testing effectiveness (Phase 2)WithdrawnNCT03173859
What this trial is testing

Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
University of Athens
Not applicableActive Not RecruitingNCT02735252
What this trial is testing

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Who this might be right for
Prostate CancerAdvanced Renal Cell CarcinomaAdvanced Urothelial Carcinoma+1 more
University of California, San Francisco 156
Early research (Phase 1)Study completedNCT03569280
What this trial is testing

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Who this might be right for
Castration-Resistant Prostate Cancer
Kangpu Biopharmaceuticals, Ltd. 16
Testing effectiveness (Phase 2)Looking for participantsNCT06241846
What this trial is testing

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT01503229
What this trial is testing

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
University of Washington 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383079
What this trial is testing

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerMCRPCProstate Cancer
Peter MacCallum Cancer Centre, Australia 36
Early research (Phase 1)Looking for participantsNCT06636123
What this trial is testing

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Who this might be right for
Castration-resistant Prostate Cancer
Virginia Commonwealth University 30
Very early researchWithdrawnNCT07052760
What this trial is testing

Imaging of Solid Tumors Using DLL3 SPECT

Who this might be right for
Solid Tumor CancerCastration Resistant Prostate CancerCastration Resistant Prostate Cancer (CRPC)+1 more
Thomas Hope
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07592910
What this trial is testing

Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma)
Prostate Cancer Clinical Trials Consortium 60
Testing effectiveness (Phase 2)Ended earlyNCT04918810
What this trial is testing

Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostatic Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 6
Not applicableLooking for participantsNCT06334809
What this trial is testing

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

Who this might be right for
Prostate Cancer
Fondazione del Piemonte per l'Oncologia 400
Next Page